Table 4 Clinical and demographic descriptors for each of the c-SLE malignancy cases
Demographic and clinical characteristics | c-SLE Cases | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Median (min–max) | |
Age at malignancy diagnosis (years) | 24 | 14 | 12 | 16 | 15 | 13 | 32 | 30 | 27 | 32 | 27 | 22 | 23 (12–32) |
Age at cSLE diagnosis | 10 | 14 | 11 | 10 | 11 | 12 | 13 | 17 | 12 | 16 | 12 | 13 | 12 (10–17) |
cSLE duration (years) | 14 | 0.2 | 1.8 | 6.1 | 4 | 1.3 | 19 | 13 | 16 | 16 | 12 | 8.7 | 10 (0.2–19) |
Gender (F:M) | F | F | F | F | M | F | F | F | F | F | F | F | 11:1 |
Specific Malignancy | SC | HL | NHL | NHL | TT | OL | AC | ALL | SC | SC | SC | C | – |
SLEDAI 2K scores | 22 | 31 | 13 | 10 | 4 | 38 | 8 | 1 | 3 | 0 | 12 | 7 | 9 (0–38) |
SLICC/ACR-DI scores | 5 | – | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 (1–5) |
Drugs ever used during c-SLE follow up | PDN MPDN HXC MMF AZA CYC RTX | PDN MPDN HXC MMF AZA | PDN HXC AZA | PDN HXC AZA | PDN MPDN HXC AZA MMF CYC IVIG | PDN HXC | PDN HXC UNK | HXC UNK | PDN UNK | HXC MMF UNK | PDN HXC MMF UNK | PDN HXC MTX | |